Amos Tanay is supported by grants from the European Research Council (ERC-2012-StG No 309706), the European Network of Excellence EpiGeneSys, and the Israeli Science Foundation

(ISF 711313). AT is SCH772984 chemical structure an incumbent of the Robert Edward and Roselyn Rich Manson Career Development Chair. “
“Current Opinion in Genetics & Development 2014, 26:16–23 This review comes from a themed issue on Molecular and genetic bases of disease Edited by Cynthia T McMurray and Jan Vijg For a complete overview see the Issue and the Editorial Available online 5th June 2014 http://dx.doi.org/10.1016/j.gde.2014.04.003 0959-437X/© 2014 Elsevier Ltd. All rights reserved. The impaired ability to maintain organelle and protein homeostasis, or proteostasis, has been implicated as a common cause of numerous human diseases. Chaperones and the two main proteolytic systems that participate in this cellular quality control, the proteasome and the lysosomal system or autophagy, have become attractive targets in the treatment of protein conformation diseases. In the case of autophagy, the main topic of this review, its additional role in maintaining the cellular energetic balance has made autophagic failure relevant for human metabolic disorders, further increasing the interest of the biomedical community

in this process. The first pharmacologic modulators

of autophagy have made their debut in clinical trials for cancer, myopathies, genetic liver disorders and heart conditions learn more (Database: ClinicalTrials.gov) and searches for genetic polymorphisms in autophagy-related genes (ATG) that could affect predisposition to metabolic diseases or neurodegeneration are under way. As the relevance of autophagy to human disease increases, further consideration as to what the autophagic changes are ‘telling us’ about each disease becomes necessary. In this Methocarbamol review, we comment on common themes concerning the relationship between autophagy and disease that we foresee will become important in the future implementation of therapies that target the autophagic process. The degradation of intracellular components by lysosomes, or autophagy, occurs in a multi-step fashion that requires recognition of the substrate to be degraded (or cargo), delivery to lysosomes, degradation and recycling of the breakdown products. Depending on the molecular components involved in each of these steps, three types of autophagy have been identified to co-exist in most cell types (Figure 1). In macroautophagy, cargo is sequestered inside double-membrane vesicles (autophagosomes) for delivery to lysosomes through vesicular fusion (Box 1) [1].